New drug seeks to clear severe skin plaques
Disease control
Not yet recruiting
This study aims to find the best dose of an investigational drug called ORKA-002 for treating moderate-to-severe plaque psoriasis. About 160 adults with this skin condition will receive either one of three different doses of the drug or a placebo for 16 weeks. Researchers will me…
Phase: PHASE2 • Sponsor: Oruka Therapeutics, Inc. • Aim: Disease control
Last updated Mar 20, 2026 14:47 UTC